Multiple solid tumors
Conditions
Interventions
experimental group:Camrelizumab + Thalidomide
Sponsors
Lixin County People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 85 years, male or female; 2. Patients with advanced liver cancer, lung cancer, stomach cancer, colorectal cancer, esophageal cancer and other solid tumors who have previously received standard first-line and/or second-line systemic chemotherapy for disease progression or who cannot tolerate chemotherapy; 3.ECOG PS score 0-3; 4. Estimated survival >=3 months; 5. The main organs were functioning normally, and no patients with serious dysfunction of blood, heart, lung, liver, kidney, bone marrow or immune deficiency were found. The laboratory tests met the following requirements: (1) Hemoglobin >=75 g/L; (2) White blood cell >=3.0x10^9/L; Neutrophil count >=1.5x10^9/L; (3) Platelet >=70x10^9/L; (4) Liver function (ASpartate aminotransferase AST or ALT) <=2.5 times the upper limit of normal value (ULN); (5) Renal function (serum creatinine sCr) <=1.5 times the upper limit of normal value (ULN); (6) Total bilirubin (TBIL) <=1.5 times normal upper limit (ULN); (7) urinary protein and occult blood < 2+; Fecal occult blood < 2+. 6. Subjects voluntarily joined the study and signed informed consent with good compliance and follow-up; 7. Researchers believe that treatment can benefit.
Exclusion criteria
Exclusion criteria: 1. Persons who have been proved to be allergic to the test drug and/or its excipients; 2. Subjects who are receiving additional chemotherapy, radiation, targeted or immunotherapy; 3. Have any active autoimmune diseases or a history of autoimmune diseases; 4. Patients with congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA>=500 IU/mL), hepatitis C (positive hepatitis C antibody, and HCV-RNA higher than the detection limit of analysis method) or co-infection with hepatitis B and hepatitis C; or have a history of organ transplantation; 5. Clinical symptoms or diseases of the heart that are not well controlled; 6. Pregnant or lactating women; 7. Men and women who attempted pregnancy within 4 weeks before and after oral thalidomide treatment; 8. Recent history of thrombosis; 9. Patients not suitable for inclusion in this study as judged by the investigator; 10. Patients with internal systemic diseases and psychiatric diseases are not suitable for chemotherapy; 11. Patients with acute infection requiring antibiotic treatment; 12. Patients who had participated in clinical trials of other drugs within four weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public ContactZhao Dong
Lixin County People's Hospital
Outcome results
None listed